Literature DB >> 10605007

Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival.

W P Min1, R Gorczynski, X Y Huang, M Kushida, P Kim, M Obataki, J Lei, R M Suri, M S Cattral.   

Abstract

Polarization of an immune response toward tolerance or immunity is dictated by the interactions between T cells and dendritic cells (DC), which in turn are modulated by the expression of distinct cell surface molecules, and the cytokine milieu in which these interactions are taking place. Genetic modification of DC with genes coding for specific immunoregulatory cell surface molecules and cytokines offers the potential of inhibiting immune responses by selectively targeting Ag-specific T cells. In this study, the immunomodulatory effects of transfecting murine bone marrow-derived DC with Fas ligand (FasL) were investigated. In this study, we show that FasL transfection of DC markedly augmented their capacity to induce apoptosis of Fas+ cells. FasL-transfected DC inhibited allogeneic MLR in vitro, and induced hyporesponsiveness to alloantigen in vivo. The induction of hyporesponsiveness was Ag specific and was dependent on the interaction between FasL on DC and Fas on T cells. Finally, we show that transfusion of FasL-DC significantly prolonged the survival of fully MHC-mismatched vascularized cardiac allografts. Our findings suggest that DC transduced with FasL may facilitate the development of Ag-specific unresponsiveness for the prevention of organ rejection. Moreover, they highlight the potential of genetically engineering DC to express other genes that affect immune responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10605007     DOI: 10.4049/jimmunol.164.1.161

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

1.  Bone marrow-derived dendritic cells from experimental allergic encephalomyelitis induce immune tolerance to EAE in Lewis rats.

Authors:  B G Xiao; Y M Huang; J S Yang; L Y Xu; H Link
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

2.  Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis.

Authors:  Y Morita; J Yang; R Gupta; K Shimizu; E A Shelden; J Endres; J J Mulé; K T McDonagh; D A Fox
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 3.  Dendritic cells, T cell tolerance and therapy of adverse immune reactions.

Authors:  P A Morel; M Feili-Hariri; P T Coates; A W Thomson
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

Review 4.  Alternatives to immunosuppressive drugs in human islet transplantation.

Authors:  Alison Anne Cotterell; Norma Sue Kenyon
Journal:  Curr Diab Rep       Date:  2002-08       Impact factor: 4.810

Review 5.  Induction of RNA interference in dendritic cells.

Authors:  Mu Li; Hua Qian; Thomas E Ichim; Wei-Wen Ge; Igor A Popov; Katarzyna Rycerz; John Neu; David White; Robert Zhong; Wei-Ping Min
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

6.  Endogenous dendritic cells mediate the effects of intravenously injected therapeutic immunosuppressive dendritic cells in transplantation.

Authors:  Sherrie J Divito; Zhiliang Wang; William J Shufesky; Quan Liu; Olga A Tkacheva; Angela Montecalvo; Geza Erdos; Adriana T Larregina; Adrian E Morelli
Journal:  Blood       Date:  2010-06-24       Impact factor: 22.113

7.  Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice.

Authors:  Esma S Yolcu; Hong Zhao; Laura Bandura-Morgan; Chantale Lacelle; Kyle B Woodward; Nadir Askenasy; Haval Shirwan
Journal:  J Immunol       Date:  2011-11-07       Impact factor: 5.422

8.  CD40 expression in Wehi-164 cell line.

Authors:  Mohammad Hossein Karimi; Padideh Ebadi; Ali Akbar Pourfathollah; Zahra Soheila Soheili; Seyed Mohammad Moazzeni
Journal:  Cytotechnology       Date:  2010-05-23       Impact factor: 2.058

Review 9.  Management of high-risk corneal transplantation.

Authors:  Antonio Di Zazzo; Ahmad Kheirkhah; Tulio B Abud; Sunali Goyal; Reza Dana
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

Review 10.  Application of cellular gene therapy for rheumatoid arthritis.

Authors:  Atsuo Nakajima
Journal:  Mod Rheumatol       Date:  2006       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.